Chinese biopharmaceutical company Sinovac Biotech Ltd (NASDAQ:SVA) stated on Thursday its net income of USD5.1bn (USD51.42 per basic and USD44.80 per diluted common share) for the six months ended 30 June 2021.
This marks a rise in earnings when compared with a net loss of USD12.6m (USD0.13 loss per basic and diluted common share) in the prior year period.
Sales of USD11.0bn were reported for the six months ended 30 June 2021, up over USD67.7m in the prior year period, due to higher sales of CoronaVac and sales growth of its other products as the COVID-19 pandemic subsided in China and vaccine schedules returned to normal.
R&D expenses of USD53.9m were recorded for the six months ended 30 June 2021, an increase versus R&D expenses of USD20.1m in the prior year period.
SINOVAC swings to net income of USD5.1bn for first half of 2021
UK Government to Purchase Additional 1.75m Courses of Molnupiravir
Rite Aid Corporation dips to net loss from continuing operations of USD36.1m in Q3 fiscal 2022
European Commission Expands Indication for Veklury for the Treatment of Adults
Eli Lilly increases quarterly dividend
CEPI Partners with Affinivax to Develop a Novel COVID-19 Vaccine to Target Variants